D Hong, K H Kang, J M Barnes, B C Baumann, R J Brenneman, Y Huang, J E Zoberi, J L Garcia-Ramirez, D Caruthers, M B Altman, H A Gay
PURPOSE/OBJECTIVE(S): Single-fraction high dose rate (HDR) prostate brachytherapy has shown improved actuarial biochemical control rates from 66% to 82% with dose escalation from 19 to 20.5 Gy, respectively, but is still inferior to the reported low dose rate brachytherapy control rates of over 90%. We aimed to identify whether dose escalation to 21, 23, and 25 Gy can be safely accomplished. MATERIALS/METHODS: Patients with previously untreated, pathologically confirmed, low-risk (cT1-T2a, Gleason ≤6, PSA <10 ng/mL) or favorable intermediate risk (Gleason 3+4, percentage of positive biopsy cores <50%, ≤1 NCCN intermediate risk factor) prostate adenocarcinoma were enrolled from a single institution...
October 1, 2023: International Journal of Radiation Oncology, Biology, Physics